Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares are down more than -27.48% this year and recently decreased -5.34% or -$0.85 to settle at $15.07. Kosmos Energy Ltd. (NYSE:KOS), on the other hand, is down -13.14% year to date as of 04/02/2018. It currently trades at $5.95 and has ...

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary Salix is fostering a new two-way conversation between health care providers and irritable bowel syndrome with diarrhea (IBS-D) patients: a national education campaign called “Let's Talk 2.” The goal here is to encourage patients, ...

After picking up a cool $62.7 million in 2016—most of which was equity that'll pay off down the line—Papa racked up (PDF) just $4.9 million last year. And the difference wasn't just equity. In addition to the missing $42 million in stock awards and $10 million in option awards, 2017's tally also lacked the ...

After more than two years since collapsing by over 90%, Valeant Pharmaceuticals Intl Inc (TSX:VRX)(NYSE:VRX) still garners a loyal following of investors that anxiously await the once darling of the market to make a recovery. In the aftermath of that epic collapse, Valeant was left with over US$30 billion in ...

... for Rifamycin has been submitted to the FDA seeking market authorization for the treatment of traveler's diarrhea under an expedited review process in the U.S. Rifamycin, if approved, would compete with Valeant Pharmaceuticals' largest product, Xifaxan, which is indicated to treat both traveler's diarrhea ...

Valeant Pharmaceuticals (NYSE:VRX), a specialty pharmaceutical company, saw its shares sink by 11.8% last month, according to S&P Global Market Intelligence. What went wrong? The drugmaker's shares retreated largely in response to its weaker-than-expected fourth-quarter and full-year earnings ...

The latest earnings release Valeant Pharmaceuticals International Inc's (NYSE:VRX) announced in December 2017 indicated that the business finally turned profitable after delivering negative earnings on average over the past couple of years. Today I want to provide a brief commentary on how market ...

Valeant Pharmaceuticals Int'l. (VRX) could become a case study in business school but in the meantime we need to deal with its rallies and declines in a non-academic setting. What do the charts and indicators look like today? Let's check. In this daily bar chart of VRX, below, we can see that prices broke ...

Valeant's Q4 results were more or less inline, but there was no surprise as many hoped. The company will have another difficult year in 2018, and can hope for growth in 2019. However, in the end, I think management will turn the company around. As such, there is a big chance shares become very ...

The problem Valeant now faces is two fold. U.S. Diversified is the company's highest margin business. It has a segment EBITDA margin (excluding corporate allocations) of 70% vs. about 37% for other segments. The more it declines the more it hurts the company's margins. Secondly, financial engineering ...

FILE PHOTO: The headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec FILE PHOTO: File photo of the headquarters of Valeant Pharmaceuticals International Inc in Laval Thomson Reuters (Reuters) - Valeant Pharmaceuticals on Wednesday reported a profit in the fourth quarter compared to a ...

Valeant Pharmaceuticals on Wednesday gave a weaker-than-expected revenue forecast for 2018, as several of its major drugs face more competition from generics. The Canada-based drugmaker's revenue will also be pressured as the company continues selling off businesses to free up cash and reduce ...

The backstory is that CEO Joseph Papa has acted to quickly to stabilize the business by selling off a number of non-core segments, such as the cancer unit Dendreon, the female viagra developer Sprout Pharmaceuticals, as well as the skin-care subsidiary Obagi Medical Products. By doing so, Papa has ...

When Valeant Pharmaceuticals (VRX) reports quarterly earnings on Feb. 28 before the market opens, shareholders will look for more data points pointing to revenue stabilization and even growth in its core businesses. Markets are on the fence with the stock. After its last earnings report, investors bid the ...

Valeant Pharmaceuticals (NYSE:VRX) stock started the year off on a sour note by shedding nearly 11% of its value in January, according to S&P Global Market Intelligence . What's behind this double-digit drop? The specialty pharma's stock tumbled immediately after analysts at Goldman Sachs issued a ...

White hot financial markets and animal spirits since President Trump's election have been boons to Valeant's asset sales. After cutting its debt load by $6 billion bulls have trumpeted the company's survival, and the shares have spiked largely based on sentiment. Of note is that Valeant recorded $2.8 billion ...

When Valeant Pharmaceuticals (NYSE:VRX) reported its third-quarter results in November, CEO Joe Papa stated that the "performance demonstrates our continued progress in the turnaround of Valeant." And he had a point. Valeant posted a profit during the quarter thanks to a tax benefit. The stock even ...